Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients (≥18 and ≤ 75 years of age) of either sex~* Willingness to participate and comply with procedures by signing a written informed consent~* Moderate/severe persistent allergic rhinitis with a history of intermittent asthma from at least 2 years and actual asthma (symptoms in the last 4 weeks)~* To qualify at the randomization visit the daily average of the T5SS \[(Morning-time T5SS + Evening-time T5SS)/2\] had to be ≥ 6 in at least 4 days during the 1 week run-in period~* Positive (weal diameter \>3 mm) skin prick test (SPT) and/or CAP-RAST (class II or higher) performed in the 6 months prior to the start of the trial were required for at least house dust mite and 1 pollen allergen (grass or Parietaria, IgE level \>3.5 U/mL)~* All prior medication washout times had been observed~* Female volunteers of childbearing potential had to agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 30 days after stopping the medication~* Negative urine pregnancy test~* Free of any clinically relevant disease that would have interfered with study evaluations~* Able to adhere to the dosing and visit schedules, and agree to record symptom severity scores and use of IMP and rescue medications in a daily diary~Exclusion Criteria:~* Female who was or intended to become pregnant during the study or within 12 weeks after study completion~* Nursing, or intended to be nursing during the study or within 12 months after study completion~* Taking medications prohibited during the study or had not complied with the requirements for the designated washout periods for any of the prohibited medications~* Anatomical abnormalities of the nose (turbinate hypertrophy, septal deviation, polyps)~* Acute or chronic sinusitis currently being treated with antibiotics and/or topical or oral decongestants~* Rhinitis medicamentosa~* Evidence of persistent asthma, or asthma with daytime and nighttime symptoms not controlled by short-acting beta2-adrenoceptor agonists~* Asthma requiring chronic use of inhaled or systemic corticosteroids~* Upper respiratory tract or sinus infection that required antibiotic therapy and had not had at least a 14-day wash-out period prior to the run-in period, or had a viral upper respiratory infection within 7 days prior to screening~* Dependence on nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids~* Undergoing a progressive course of immunotherapy (hyposensitization). Subjects on a regular maintenance schedule prior to the screening visit were eligible for study inclusion; however, subject could not receive hyposensitization treatment within 24 hours prior to any study visit~* Diagnosed of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas)~* Concomitant medical problem~* Had any of the following clinical conditions: active or quiescent tuberculosis infection of the respiratory tract, untreated fungal, bacterial, systemic viral infections or ocular herpes simplex~* Smoked or had smoked within the previous 6 months~* Member of the staff, affiliated with, or family member of the staff personnel directly involved with this study~* Previously randomized into this study~* Any other clinically significant deviation from normal in the physical examination or medical history that could interfere with the study evaluation or affect subject safety~* In a situation or condition that could interfere with participation in the study~* Used any drug or device in an investigational protocol in the 30 days prior to visit 1~* Participating in other clinical studies~* Allergic or has sensitivity to the study drug or its excipients~* Compromised ability to provide informed consent~* History of non-compliance with medication or treatment protocols

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mometasone furoate nasal spray (Type: EXPERIMENTAL): Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
- Placebo nasal spray (Type: PLACEBO_COMPARATOR): Placebo nasal spray once daily (two puffs per nostril) in the morning.

Based on this trial design, predict the completion outcome and termination type (if applicable).